A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Daprodustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Jul 2017 Planned primary completion date changed from 18 Oct 2019 to 15 Nov 2019.
- 10 Jul 2017 Planned primary completion date changed from 15 Nov 2019 to 18 Oct 2019.
- 26 May 2017 Status changed from not yet recruiting to recruiting.